^
Association details:
| Biomarker: | ERCC2 D312N |
|---|---|
| Cancer: | Osteosarcoma |
| Drug: | cisplatin (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients
Excerpt:
Eight single nucleotide polymorphisms in ERCC2, XPC, XPA, ERCC1, ERCC4 and ERCC5 genes were analyzed in 91 patients diagnosed with osteosarcoma and treated with cisplatin….Regarding the other variant in the ERCC2 gene, the ERCC2 Asp312Asn polymorphism, we observed a trend of an increased risk of poor tumor response and reduced EFS, but without reaching the statistical significance.
DOI:
10.1038/tpj.2009.19
